Chemical: Drug
quetiapine

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.



PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

List of all variant annotations for quetiapine

Gene ? Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No VIP available VA CYP1A2 *1A N/A N/A N/A
No VIP available No VIP available VA CYP1A2 *1C N/A N/A N/A
No VIP available No VIP available VA CYP1A2 *1F N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *1 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *2 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *4 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *4 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *6 N/A N/A N/A
No VIP available CA VA SLC6A4 HTTLPR long form (L allele) N/A N/A N/A
No VIP available CA VA SLC6A4 HTTLPR short form (S allele) N/A N/A N/A
No VIP available CA VA
rs10042486 NC_000005.10:g.63965502C>T, NC_000005.9:g.63261329C>T, NG_032816.1:g.1791G>A
C > T
SNP
No VIP available No Clinical Annotations available VA
rs10214163 NC_000005.10:g.75998585C>T, NC_000005.9:g.75294410C>T, rs386511075, rs58502419, rs61727521, rs74290936
C > T
SNP
No VIP available No Clinical Annotations available VA
rs1045642 NC_000007.13:g.87138645A>G, NC_000007.14:g.87509329A>G, NG_011513.1:g.208920T>C, NM_000927.4:c.3435T>C, NP_000918.2:p.Ile1145=, rs10239679, rs11568726, rs117328163, rs17210003, rs2229108, rs386513066, rs60023214, rs9690664
A > G
SNP
I1145I
No VIP available CA VA
rs1049353 NC_000006.11:g.88853635C>T, NC_000006.12:g.88143916C>T, NM_001160226.1:c.1359G>A, NM_001160258.1:c.1359G>A, NM_001160259.1:c.1359G>A, NM_016083.4:c.1359G>A, NM_033181.3:c.1260G>A, NP_001153698.1:p.Thr453=, NP_001153730.1:p.Thr453=, NP_001153731.1:p.Thr453=, NP_057167.2:p.Thr453=, NP_149421.2:p.Thr420=, XM_005248649.1:c.1359G>A, XM_005248650.1:c.1359G>A, XM_005248650.3:c.1359G>A, XM_005248651.1:c.1260G>A, XM_005248652.1:c.1176G>A, XM_006715330.2:c.1359G>A, XM_011535424.1:c.1359G>A, XM_011535425.1:c.1359G>A, XM_011535426.1:c.1359G>A, XM_011535427.1:c.1359G>A, XM_011535428.1:c.1359G>A, XP_005248706.1:p.Thr453=, XP_005248707.1:p.Thr453=, XP_005248708.1:p.Thr420=, XP_005248709.1:p.Thr392=, XP_006715393.1:p.Thr453=, XP_011533726.1:p.Thr453=, XP_011533727.1:p.Thr453=, XP_011533728.1:p.Thr453=, XP_011533729.1:p.Thr453=, XP_011533730.1:p.Thr453=, rs17264339, rs3173203, rs386513644, rs56973242
C > T
SNP
T453T
No VIP available No Clinical Annotations available VA
rs10848635 NC_000012.11:g.2316195T>A, NC_000012.12:g.2207029T>A, NG_008801.2:g.241244T>A, NM_000719.6:c.477+86599T>A, NM_001129827.1:c.477+86599T>A, NM_001129829.1:c.477+86599T>A, NM_001129830.1:c.477+86599T>A, NM_001129830.2:c.477+86599T>A, NM_001129831.1:c.477+86599T>A, NM_001129832.1:c.477+86599T>A, NM_001129833.1:c.477+86599T>A, NM_001129834.1:c.477+86599T>A, NM_001129835.1:c.477+86599T>A, NM_001129836.1:c.477+86599T>A, NM_001129837.1:c.477+86599T>A, NM_001129838.1:c.477+86599T>A, NM_001129839.1:c.477+86599T>A, NM_001129840.1:c.477+86599T>A, NM_001129841.1:c.477+86599T>A, NM_001129842.1:c.477+86599T>A, NM_001129843.1:c.477+86599T>A, NM_001129844.1:c.477+86599T>A, NM_001129846.1:c.477+86599T>A, NM_001167623.1:c.477+86599T>A, NM_001167624.2:c.477+86599T>A, NM_001167625.1:c.477+86599T>A, NM_199460.3:c.477+86599T>A, XM_005253765.1:c.567+86599T>A, XM_005253766.1:c.486+86599T>A, XM_005253767.1:c.486+86599T>A, XM_005253768.1:c.486+86599T>A, XM_005253769.1:c.486+86599T>A, XM_005253770.1:c.486+86599T>A, XM_005253771.1:c.486+86599T>A, XM_005253772.1:c.486+86599T>A, XM_005253773.1:c.486+86599T>A, XM_005253774.1:c.486+86599T>A, XM_005253775.1:c.486+86599T>A, XM_005253776.1:c.486+86599T>A, XM_005253777.1:c.486+86599T>A, XM_005253778.1:c.486+86599T>A, XM_005253779.1:c.486+86599T>A, XM_005253780.1:c.486+86599T>A, XM_005253781.1:c.486+86599T>A, XM_005253782.1:c.486+86599T>A, XM_005253783.1:c.486+86599T>A, XM_005253784.1:c.486+86599T>A, XM_005253785.1:c.486+86599T>A, XM_005253786.1:c.486+86599T>A, XM_005253787.1:c.486+86599T>A, XM_006719017.1:c.567+86599T>A, XM_011521018.1:c.-642+86599T>A, XM_011521020.1:c.567+86599T>A, XM_011521021.1:c.477+86599T>A, XM_011521022.1:c.477+86599T>A, XM_011521023.1:c.477+86599T>A, rs60528912
T > A
SNP
No VIP available No Clinical Annotations available VA
rs1128503 NC_000007.13:g.87179601A>G, NC_000007.14:g.87550285A>G, NG_011513.1:g.167964T>C, NM_000927.4:c.1236T>C, NP_000918.2:p.Gly412=, rs116989428, rs17276907, rs2032587, rs2229105, rs28365046, rs386518005, rs58257317
A > G
SNP
G412G
No VIP available No Clinical Annotations available VA
rs11960832 NC_000005.10:g.76219161C>T, NC_000005.9:g.75514986C>T, NM_001297716.1:c.913+9274C>T, NM_014979.3:c.913+9274C>T, XM_005248470.1:c.913+9274C>T, XM_011543281.1:c.913+9274C>T, XM_011543282.1:c.160+9274C>T, rs58899392, rs60969535
C > T
SNP
No VIP available No Clinical Annotations available VA
rs12970134 NC_000018.10:g.60217517G>A, NC_000018.9:g.57884750G>A, rs60401193
G > A
SNP
No VIP available No Clinical Annotations available VA
rs1414334 NC_000023.10:g.114138144C>G, NC_000023.11:g.114903581C>G, NG_012082.2:g.324497C>G, NM_000868.3:c.551-3008C>G, NM_001256760.2:c.551-3008C>G, NM_001256761.2:c.456-3008C>G, NW_004070891.1:g.572383C>G, rs59611151
C > G
SNP
No VIP available CA VA
rs1415744 NC_000006.11:g.146022531T>C, NC_000006.12:g.145701395T>C, NG_012832.1:g.39461A>G, NM_001018041.1:c.302-15099A>G, NM_005670.3:c.302-15099A>G, XM_005267139.1:c.302-15099A>G, XM_006715564.2:c.302-15099A>G, XM_011536113.1:c.302-15099A>G, XM_011536114.1:c.302-15099A>G, XM_011536115.1:c.302-15099A>G, rs56685907
T > C
SNP
No VIP available No Clinical Annotations available VA
rs17782313 NC_000018.10:g.60183864T>C, NC_000018.9:g.57851097T>C, rs59090733, rs59781239
T > C
SNP
No VIP available No Clinical Annotations available VA
rs1800497 NC_000011.10:g.113400106G>A, NC_000011.9:g.113270828G>A, NG_012976.1:g.17316G>A, NM_178510.1:c.2137G>A, NP_848605.1:p.Glu713Lys, XM_011542736.1:c.2170G>A, XM_011542737.1:c.2140G>A, XM_011542738.1:c.1948G>A, XP_011541038.1:p.Glu724Lys, XP_011541039.1:p.Glu714Lys, XP_011541040.1:p.Glu650Lys, rs117686243, rs4134623, rs4245144, rs59538675
G > A
SNP
E713K
No VIP available CA VA
rs1806201 NC_000012.11:g.13717508G>A, NC_000012.12:g.13564574G>A, NG_031854.1:g.420515C>T, NM_000834.3:c.2664C>T, NP_000825.2:p.Thr888=, XM_005253351.1:c.450C>T, XM_005253351.2:c.450C>T, XM_011520628.1:c.2664C>T, XM_011520629.1:c.2664C>T, XM_011520630.1:c.2664C>T, XP_005253408.1:p.Thr150=, XP_011518930.1:p.Thr888=, XP_011518931.1:p.Thr888=, XP_011518932.1:p.Thr888=, rs17220215, rs3751259, rs60615287
G > A
SNP
T888T
No VIP available No Clinical Annotations available VA
rs2032582 NC_000007.13:g.87160618A>C, NC_000007.13:g.87160618A>T, NC_000007.14:g.87531302A>C, NC_000007.14:g.87531302A>T, NG_011513.1:g.186947T>A, NG_011513.1:g.186947T>G, NM_000927.4:c.2677T>A, NM_000927.4:c.2677T>G, NP_000918.2:p.Ser893Ala, NP_000918.2:p.Ser893Thr, rs10228331, rs2229106, rs386553610, rs57135550, rs9641018
A > C
SNP
S893A
No VIP available No Clinical Annotations available VA
rs2134227 NC_000005.10:g.76104642C>G, NC_000005.9:g.75400467C>G, NM_001297716.1:c.-102+21130C>G, NM_014979.3:c.-102+21130C>G, XM_005248470.1:c.-102+21130C>G, XM_011543281.1:c.-102+20329C>G, rs59248082, rs60827107
C > G
SNP
No VIP available No Clinical Annotations available VA
rs2283271 NC_000012.11:g.2182298T>A, NC_000012.12:g.2073132T>A, NG_008801.2:g.107347T>A, NM_000719.6:c.49+19521T>A, NM_001129827.1:c.49+19521T>A, NM_001129829.1:c.49+19521T>A, NM_001129830.1:c.49+19521T>A, NM_001129830.2:c.49+19521T>A, NM_001129831.1:c.49+19521T>A, NM_001129832.1:c.49+19521T>A, NM_001129833.1:c.49+19521T>A, NM_001129834.1:c.49+19521T>A, NM_001129835.1:c.49+19521T>A, NM_001129836.1:c.49+19521T>A, NM_001129837.1:c.49+19521T>A, NM_001129838.1:c.49+19521T>A, NM_001129839.1:c.49+19521T>A, NM_001129840.1:c.49+19521T>A, NM_001129841.1:c.49+19521T>A, NM_001129842.1:c.49+19521T>A, NM_001129843.1:c.49+19521T>A, NM_001129844.1:c.49+19521T>A, NM_001129846.1:c.49+19521T>A, NM_001167623.1:c.49+19521T>A, NM_001167624.2:c.49+19521T>A, NM_001167625.1:c.49+19521T>A, NM_199460.3:c.49+19521T>A, XM_005253765.1:c.140-42092T>A, XM_005253766.1:c.49+19521T>A, XM_005253767.1:c.49+19521T>A, XM_005253768.1:c.49+19521T>A, XM_005253769.1:c.49+19521T>A, XM_005253770.1:c.49+19521T>A, XM_005253771.1:c.49+19521T>A, XM_005253772.1:c.49+19521T>A, XM_005253773.1:c.49+19521T>A, XM_005253774.1:c.49+19521T>A, XM_005253775.1:c.49+19521T>A, XM_005253776.1:c.49+19521T>A, XM_005253777.1:c.49+19521T>A, XM_005253778.1:c.49+19521T>A, XM_005253779.1:c.49+19521T>A, XM_005253780.1:c.49+19521T>A, XM_005253781.1:c.49+19521T>A, XM_005253782.1:c.49+19521T>A, XM_005253783.1:c.49+19521T>A, XM_005253784.1:c.49+19521T>A, XM_005253785.1:c.49+19521T>A, XM_005253786.1:c.49+19521T>A, XM_005253787.1:c.49+19521T>A, XM_006719017.1:c.140-42092T>A, XM_011521018.1:c.-1070+19521T>A, XM_011521020.1:c.140-42092T>A, XM_011521021.1:c.49+19521T>A, XM_011521022.1:c.49+19521T>A, XM_011521023.1:c.49+19521T>A, rs17801062, rs57218195
T > A
SNP
No VIP available CA VA
rs2412459 NC_000015.10:g.40003758C>T, NC_000015.9:g.40295959C>T, NG_034053.1:g.74635C>T, NM_001013703.3:c.3357+444C>T, XM_005254392.1:c.3357+444C>T, XM_005254393.1:c.3357+444C>T, XM_011521599.1:c.3357+444C>T, XM_011521600.1:c.3357+444C>T, rs57614854
C > T
SNP
No VIP available No Clinical Annotations available VA
rs31244 NC_000005.10:g.76298918G>A, NC_000005.9:g.75594743G>A, NM_001297716.1:c.1627G>A, NM_014979.3:c.1627G>A, NP_001284645.1:p.Asp543Asn, NP_055794.3:p.Asp543Asn, XM_005248470.1:c.1627G>A, XM_011543281.1:c.1627G>A, XM_011543282.1:c.874G>A, XP_005248527.1:p.Asp543Asn, XP_011541583.1:p.Asp543Asn, XP_011541584.1:p.Asp292Asn, XR_948491.1:n.272-733C>T, rs58027942
G > A
SNP
D543N
No VIP available CA VA
rs324420 NC_000001.10:g.46870761C>A, NC_000001.11:g.46405089C>A, NG_012195.1:g.15823C>A, NM_001441.2:c.385C>A, NP_001432.2:p.Pro129Thr, XM_005270624.1:c.385C>A, XM_005270625.1:c.385C>A, XP_005270681.1:p.Pro129Thr, XP_005270682.1:p.Pro129Thr, XR_246250.1:n.463C>A, rs57947754
C > A
SNP
P129T
No VIP available No Clinical Annotations available VA
rs35793 NC_000010.10:g.79183038C>G, NC_000010.11:g.77423280C>G, NG_012270.1:g.219540G>C, NM_001014797.2:c.379-19257G>C, NM_001161352.1:c.379-19257G>C, NM_001161353.1:c.379-19257G>C, NM_001271518.1:c.379-172024G>C, NM_001271519.1:c.379-19257G>C, NM_002247.3:c.379-19257G>C, XM_005269773.1:c.379-19257G>C, XM_005269774.1:c.379-19257G>C, XM_005269775.1:c.379-19257G>C, XM_005269776.1:c.379-19257G>C, XM_005269776.2:c.379-19257G>C, XM_005269777.1:c.379-19257G>C, XM_005269778.1:c.379-19257G>C, XM_005269779.1:c.379-19257G>C, XM_005269780.1:c.379-19257G>C, XM_005269781.1:c.379-19257G>C, XM_005269782.1:c.379-19257G>C, XM_005269783.1:c.379-19257G>C, XM_005269784.1:c.379-19257G>C, XM_005269785.1:c.379-19257G>C, XM_005269786.1:c.379-19257G>C, XM_005269787.1:c.379-19257G>C, XM_005269787.2:c.379-19257G>C, XM_005269788.1:c.379-19257G>C, XM_005269789.1:c.379-19257G>C, XM_005269790.1:c.379-19257G>C, XM_005269791.1:c.379-19257G>C, XM_005269792.1:c.379-19257G>C, XM_005269793.1:c.379-19257G>C, XM_005269794.1:c.379-19257G>C, XM_005269795.1:c.379-19257G>C, XM_005269796.1:c.379-19257G>C, XM_005269797.1:c.379-19257G>C, XM_005269798.1:c.379-172024G>C, XM_005269799.1:c.379-19257G>C, XM_005269800.1:c.379-19257G>C, XM_005269801.1:c.379-19257G>C, XM_005269802.1:c.379-19257G>C, XM_006717826.1:c.379-19257G>C, XM_011539773.1:c.511-19257G>C, XM_011539774.1:c.511-19257G>C, XM_011539775.1:c.511-19257G>C, XM_011539776.1:c.511-19257G>C, XM_011539777.1:c.379-19257G>C, XM_011539778.1:c.379-19257G>C, XM_011539779.1:c.511-19257G>C, XM_011539780.1:c.379-19257G>C, XM_011539781.1:c.511-19257G>C, XM_011539782.1:c.511-19257G>C, XM_011539783.1:c.379-19257G>C, XM_011539784.1:c.511-19257G>C, XM_011539785.1:c.379-19257G>C, XR_946079.1:n.64+183C>G, XR_946080.1:n.64+183C>G, XR_946081.1:n.64+183C>G, XR_946082.1:n.65+183C>G, XR_946083.1:n.75+165C>G, XR_946084.1:n.38+259C>G, XR_946085.1:n.64+183C>G, rs16934746
C > G
SNP
No VIP available No Clinical Annotations available VA
rs3813929 NC_000023.10:g.113818520C>T, NC_000023.11:g.114584047C>T, NG_012082.2:g.4963C>T, NM_000868.3:c.-759C>T, NM_001256760.2:c.-850C>T, NM_001256761.2:c.-759C>T, NW_004070891.1:g.252849C>T, rs17326402
C > T
SNP
VIP No Clinical Annotations available No Variant Annotations available
rs4680 NC_000022.10:g.19951271G>A, NC_000022.11:g.19963748G>A, NG_011526.1:g.27009G>A, NM_000754.3:c.472G>A, NM_001135161.1:c.472G>A, NM_001135162.1:c.472G>A, NM_007310.2:c.322G>A, NP_000745.1:p.Val158Met, NP_001128633.1:p.Val158Met, NP_001128634.1:p.Val158Met, NP_009294.1:p.Val108Met, NR_039918.1:n.-5G>A, XM_005261229.1:c.472G>A, XM_011529885.1:c.586G>A, XM_011529886.1:c.586G>A, XM_011529887.1:c.472G>A, XM_011529888.1:c.472G>A, XM_011529889.1:c.472G>A, XM_011529890.1:c.472G>A, XM_011529891.1:c.472G>A, XP_005261286.1:p.Val158Met, XP_011528187.1:p.Val196Met, XP_011528188.1:p.Val196Met, XP_011528189.1:p.Val158Met, XP_011528190.1:p.Val158Met, XP_011528191.1:p.Val158Met, XP_011528192.1:p.Val158Met, XP_011528193.1:p.Val158Met, rs1131157, rs11544671, rs165688, rs17295216, rs17349704, rs17818178, rs17849308, rs17850006, rs2070104, rs3177905, rs3190784, rs3747070, rs58002978
G > A
SNP
V158M
No VIP available CA VA
rs489693 NC_000018.10:g.60215554C>A, NC_000018.9:g.57882787C>A, rs1673474
C > A
SNP
No VIP available CA VA
rs6280 NC_000003.11:g.113890815C>T, NC_000003.12:g.114171968C>T, NG_008842.2:g.32440G>A, NM_000796.5:c.25G>A, NM_001282563.2:c.25G>A, NM_001290809.1:c.25G>A, NM_033663.5:c.25G>A, NP_000787.2:p.Gly9Ser, NP_001269492.1:p.Gly9Ser, NP_001277738.1:p.Gly9Ser, NP_387512.3:p.Gly9Ser, XM_005247170.1:c.25G>A, XM_005247171.1:c.25G>A, XM_011512510.1:c.25G>A, XM_011512511.1:c.25G>A, XM_011512512.1:c.25G>A, XP_005247227.1:p.Gly9Ser, XP_005247228.1:p.Gly9Ser, XP_011510812.1:p.Gly9Ser, XP_011510813.1:p.Gly9Ser, XP_011510814.1:p.Gly9Ser, rs117481259, rs324025, rs52792556, rs59703514
C > T
SNP
G9S
No VIP available No Clinical Annotations available VA
rs646749 NC_000018.10:g.60215892G>A, NC_000018.9:g.57883125G>A, rs386602927, rs60191783
G > A
SNP
No VIP available No Clinical Annotations available VA
rs723672 NC_000012.11:g.2161561C>T, NC_000012.12:g.2052395C>T, NG_008801.2:g.86610C>T, NM_000719.6:c.-1168C>T, NM_001129827.1:c.-1168C>T, NM_001129829.1:c.-1168C>T, NM_001129830.2:c.-1168C>T, NM_001129831.1:c.-1168C>T, NM_001129832.1:c.-1168C>T, NM_001129833.1:c.-1168C>T, NM_001129834.1:c.-1168C>T, NM_001129835.1:c.-1168C>T, NM_001129836.1:c.-1168C>T, NM_001129837.1:c.-1168C>T, NM_001129838.1:c.-1168C>T, NM_001129839.1:c.-1168C>T, NM_001129840.1:c.-1168C>T, NM_001129841.1:c.-1168C>T, NM_001129842.1:c.-1168C>T, NM_001129843.1:c.-1168C>T, NM_001129844.1:c.-1168C>T, NM_001129846.1:c.-1168C>T, NM_001167623.1:c.-1168C>T, NM_001167624.2:c.-1168C>T, NM_001167625.1:c.-1168C>T, NM_199460.3:c.-1168C>T, XM_005253765.1:c.140-62829C>T, XM_005253766.1:c.-1168C>T, XM_005253767.1:c.-1168C>T, XM_005253768.1:c.-1168C>T, XM_005253769.1:c.-1168C>T, XM_005253770.1:c.-1168C>T, XM_005253771.1:c.-1168C>T, XM_005253772.1:c.-1168C>T, XM_005253773.1:c.-1168C>T, XM_005253774.1:c.-1168C>T, XM_005253775.1:c.-1168C>T, XM_005253776.1:c.-1168C>T, XM_005253777.1:c.-1168C>T, XM_005253778.1:c.-1168C>T, XM_005253779.1:c.-1168C>T, XM_005253780.1:c.-1168C>T, XM_005253781.1:c.-1168C>T, XM_005253782.1:c.-1168C>T, XM_005253783.1:c.-1168C>T, XM_005253784.1:c.-1168C>T, XM_005253785.1:c.-1168C>T, XM_005253786.1:c.-1168C>T, XM_005253787.1:c.-1168C>T, XM_006719017.1:c.140-62829C>T, XM_011521018.1:c.-2286C>T, XM_011521020.1:c.140-62829C>T, XM_011521021.1:c.-1168C>T, XM_011521022.1:c.-1168C>T, XM_011521023.1:c.-1168C>T
C > T
SNP
No VIP available No Clinical Annotations available VA
rs758723 NC_000012.11:g.2220405T>A, NC_000012.12:g.2111239T>A, NG_008801.2:g.145454T>A, NM_000719.6:c.50-3985T>A, NM_001129827.1:c.50-3985T>A, NM_001129829.1:c.50-3985T>A, NM_001129830.1:c.50-3985T>A, NM_001129830.2:c.50-3985T>A, NM_001129831.1:c.50-3985T>A, NM_001129832.1:c.50-3985T>A, NM_001129833.1:c.50-3985T>A, NM_001129834.1:c.50-3985T>A, NM_001129835.1:c.50-3985T>A, NM_001129836.1:c.50-3985T>A, NM_001129837.1:c.50-3985T>A, NM_001129838.1:c.50-3985T>A, NM_001129839.1:c.50-3985T>A, NM_001129840.1:c.50-3985T>A, NM_001129841.1:c.50-3985T>A, NM_001129842.1:c.50-3985T>A, NM_001129843.1:c.50-3985T>A, NM_001129844.1:c.50-3985T>A, NM_001129846.1:c.50-3985T>A, NM_001167623.1:c.50-3985T>A, NM_001167624.2:c.50-3985T>A, NM_001167625.1:c.50-3985T>A, NM_199460.3:c.50-3985T>A, XM_005253765.1:c.140-3985T>A, XM_005253766.1:c.50-3985T>A, XM_005253767.1:c.50-3985T>A, XM_005253768.1:c.50-3985T>A, XM_005253769.1:c.50-3985T>A, XM_005253770.1:c.50-3985T>A, XM_005253771.1:c.50-3985T>A, XM_005253772.1:c.50-3985T>A, XM_005253773.1:c.50-3985T>A, XM_005253774.1:c.50-3985T>A, XM_005253775.1:c.50-3985T>A, XM_005253776.1:c.50-3985T>A, XM_005253777.1:c.50-3985T>A, XM_005253778.1:c.50-3985T>A, XM_005253779.1:c.50-3985T>A, XM_005253780.1:c.50-3985T>A, XM_005253781.1:c.50-3985T>A, XM_005253782.1:c.50-3985T>A, XM_005253783.1:c.50-3985T>A, XM_005253784.1:c.50-3985T>A, XM_005253785.1:c.50-3985T>A, XM_005253786.1:c.50-3985T>A, XM_005253787.1:c.50-3985T>A, XM_006719017.1:c.140-3985T>A, XM_011521018.1:c.-1069-3985T>A, XM_011521020.1:c.140-3985T>A, XM_011521021.1:c.50-3985T>A, XM_011521022.1:c.50-3985T>A, XM_011521023.1:c.50-3985T>A
T > A
SNP
No VIP available CA VA
rs776746 NC_000007.13:g.99270539C>T, NC_000007.14:g.99672916T>C, NG_007938.1:g.12083G=, NG_007938.1:g.12083G>A, NM_000777.4:c.219-237A>G, NM_000777.4:c.219-237G>A, NM_001190484.2:c.219-237A>G, NM_001190484.2:c.219-237G>A, NM_001291829.1:c.-253-1A>G, NM_001291829.1:c.-253-1G>A, NM_001291830.1:c.189-237A>G, NM_001291830.1:c.189-237G>A, NR_033807.2:n.717-1A>G, NR_033807.2:n.717-1G>A, NR_033808.1:n.689-1G>A, NR_033809.1:n.581-237G>A, NR_033810.1:n.689-1G>A, NR_033811.1:n.321-1G>A, NR_033812.1:n.321-1G>A, XM_005250169.1:c.189-237G>A, XM_005250170.1:c.-357-1G>A, XM_005250171.1:c.-253-1G>A, XM_005250172.1:c.-254G>A, XM_005250173.1:c.-331-237G>A, XM_005250198.1:c.806-4288C>T, XM_006715859.2:c.219-237A>G, XM_011515843.1:c.-254A>G, XM_011515844.1:c.-229-237A>G, XM_011515845.1:c.-463-1A>G, XM_011515846.1:c.-331-237A>G, XM_011515847.1:c.-571-1A>G, XR_927383.1:n.344-237A>G, XR_927402.1:n.1466+48736T>C, rs10361242, rs11266830, rs386613022, rs58244770
C > T
SNP
No VIP available CA VA
rs7912580 NC_000010.10:g.63915972G>A, NC_000010.11:g.62156213G>A, rs57222647
G > A
SNP
No VIP available CA VA
rs951439 NC_000001.10:g.163033691C>T, NC_000001.11:g.163063901C>T, NG_023312.1:g.296C>T, rs36214199, rs386623110, rs52799590, rs57153444
C > T
SNP
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Generic Names
Trade Names
  • Quetiapin hemifumarate
  • Quetiapine fumarate
  • Quetiapine hemifumarate
  • Seroquel
  • Seroquel XR
Brand Mixture Names

PharmGKB Accession Id

PA451201

Type(s):

Drug

Description

Quetiapine is indicated for the treatment of schizophrenia as well as for the treatment of acute manic episodes associated with bipolar I disorder. The antipsychotic effect of quetiapine is thought by some to be mediated through antagonist activity at dopamine and serotonin receptors. Specifically the D1 and D2 dopamine, the alpha 1 adrenoreceptor and alpha 2 adrenoreceptor, and 5-HT1A and 5-HT2 serotonin receptor subtypes are antagonized. Quetiapine also has an antagonistic effect on the histamine H1 receptor.

Source: Drug Bank

Pharmacogenetics

Pharmacokinetics

The primary route of elimination of quetiapine is through hepatic metabolism. Major routes of metabolism involve oxidation of the alkyl side chain, oxidation of the terminal alcohol to the corresponding carboxylic acid, hydroxylation of the dibenzothiazepine ring, sulfoxidation and phase II conjugation [Article:11510628]. 7-hydroxy-quetiapine and 7-hydroxy-N-desalkylquetiapine are active metabolites and the plasma concentrations were 12.1 and 12.3%, respectively, of that of quetiapine [Article:9497016]. CYP3A4 was found to be the primary enzyme responsible for the CYP-mediated metabolism of quetiapine in vitro and in vivo [Articles:11510628, 15834460]. CYP2D6 made a small contribution to the 7-hydroxylation of quetiapine in vitro [Article:11510628] and CYP3A4 was not found to catalyze the 7-hydroxylation of quetiapine in vivo [Article:15834460]. In an in vitro study CYP3A5 was found of minor importance for the metabolism of quetiapine [Article:19022943]. A case study described significant interaction between atazanavir-ritonavir and quetiapine [Article:19857154].

Quetiapine also has moderate to strong affinity as a P-glycoprotein 1 (ABCB1) substrate and is also an inhibitor [Articles:18537577, 16145193, 12031686, 15285840]. An in vitro study, which evaluated the inhibitory effect of antipsychotics on the cellular uptake of a prototypic substrate of P-gp, found that quetiapine had inhibitory effects on P-gp activity but at concentration most likely not relevant for inhibition of P-gp activity in the blood-brain barrier [Article:16810505].

Pharmacodynamics

Quetiapine is an atypical antipsychotic with a unique receptor-binding profile. Quetiapine has moderate affinity for serotonin 2A receptors (HTR2A) [Article:11051217]. Quetiapine also has antagonist activity at alpha1adrenergic, muscarinic and histaminergic (HTH1) receptors [Article:11510628]. It has only minor affinity for dopamine D2 (DRD2) and serotonin 1A (HTR1A) receptors and very low affinity for serotonin 2C (HTR2C), alpha2 adrenergic and dopamine D1 (DRD1) receptors [Article:11510628]. However, the precise mechanism of action remains unclear.

Quetiapine is associated with measurable QTc prolongation in a study in 27 patients with psychotic disorders receiving 750 mg/day [Article:14709949].

Pharmacogenomics

The 3435T allele in exon 26 of the ABCB1 gene was associated with significantly higher placental transfer of quetiapine (P = 0.04) [Article:17259208].

Polymorphic HTR2A exhibited statistically significant, but modest, changes in atypical antipsychotic affinity [Article:20097665]. Variants in the regulator of G protein signaling 4 (RGS4) gene are found to be associated with relative responsiveness to antipsychotic treatment (perphenazine, quetiapine, ziprasidone) [Article:17588543]. A genome-wide approach to detect genetic variations underlying individual differences in response to treatment with various antipsychotics found several polymorphisms in the flavin containing monooxygenase 5 (FMO5) gene are associated with quetiapine response on the emotional distress scale [Article:19721433].

Variants in the acetyl-CoA carboxylase alpha (ACACA) gene were significantly associated with hypertriglyceridemia in patients taking olanzapine, quetiapine, chlorpromazine or mirtazapine [Article:19846279]. Neuropeptide Y (NPY) and acetyl-CoA carboxylase beta (ACACB) gene polymorphisms were investigated in association with hypercholesterolemia in patients taking olanzapine, quetiapine or chlorpromazine [Article:18031993].

Source: PharmGKB

Indication

For the treatment of schizophrenia and related psychotic disorders.

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Quetiapine's antipsychotic activity is likely due to a combination of antagonism at D2 receptors in the mesolimbic pathway and 5HT2A receptors in the frontal cortex. Antagonism at D2 receptors relieves positive symptoms while antagonism at 5HT2A receptors relieves negative symptoms of schizophrenia.

Source: Drug Bank

Pharmacology

Quetiapine is a psychotropic agent belonging to the chemical class of benzisoxazole derivatives and is indicated for the treatment of schizophrenia. Quetiapine is a selective monoaminergic antagonist with high affinity for the serotonin Type 2 (5HT 2), and dopamine type 2 (D2) receptors. Quetiapine is an antagonist at serotonin 5-HT 1A and 5HT 2, dopamine D1 and D2, histamine H1, and adrenergic alpha 1 and alpha 2 receptors. Quetiapine has no significant affinity for cholinergic muscarinic or benzodiazepine receptors. Drowsiness and orthostatic hypotension associated with use of quetiapine may be explained by its antagonism of histamine H1 and adrenergic alpha 1 receptors, respectively. Quetiapine's antagonism of adrenergic a1 receptors may explain the orthostatic hypotension observed with this drug.

Source: Drug Bank

Food Interaction

Avoid alcohol.|Take without regard to meals.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Hepatic. The major metabolic pathways are sulfoxidation, mediated by cytochrome P450 3A4 (CYP3A4), and oxidation of the terminal alcohol to a carboxylic acid. The major sulfoxide metabolite of quetiapine is inactive. Quetiapine also undergoes hydroxylation of the dibenzothiazepine ring, O-deakylation, N-dealkylation, and phase II conjugation. The 7-hydroxy and 7-hydroxy-
N-delakylated metabolites appear to be active, but are present in very low concentrations.

Source: Drug Bank

Protein Binding

83%

Source: Drug Bank

Absorption

Rapidly and well absorbed.

Source: Drug Bank

Half-Life

6 hours

Source: Drug Bank

Toxicity

Symptoms of overdose include drowsiness and sedation, tachycardia, and hypotension.

Source: Drug Bank

Route of Elimination

Elimination of quetiapine is mainly via hepatic metabolism. Following a single oral dose of 14C-quetiapine, less than 1% of the administered dose was excreted as unchanged drug, indicating that quetiapine is highly metabolized. Approximately 73% and 20% of the dose was recovered in the urine and feces, respectively.

Source: Drug Bank

Volume of Distribution

  • 10±4 L/kg

Source: Drug Bank

Chemical Properties

Chemical Formula

C21H25N3O2S

Source: Drug Bank

Isomeric SMILES

c1ccc2c(c1)C(=Nc3ccccc3S2)N4CCN(CC4)CCOCCO

Source: OpenEye

Canonical SMILES

OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12

Source: Drug Bank

Average Molecular Weight

383.507

Source: Drug Bank

Monoisotopic Molecular Weight

383.166747749

Source: Drug Bank

SMILES

OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12

Source: Drug Bank

InChI String

InChI=1S/C21H25N3O2S/c25-14-16-26-15-13-23-9-11-24(12-10-23)21-17-5-1-3-7-19(17)27-20-8-4-2-6-18(20)22-21/h1-8,25H,9-16H2

Source: Drug Bank

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

Drug Targets

Gene Description
ADRA1A (source: Drug Bank)
ADRA1B (source: Drug Bank)
ADRA1D (source: Drug Bank)
ADRA2A (source: Drug Bank)
ADRA2B (source: Drug Bank)
ADRA2C (source: Drug Bank)
CHRM1 (source: Drug Bank)
CHRM2 (source: Drug Bank)
CHRM3 (source: Drug Bank)
CHRM4 (source: Drug Bank)
CHRM5 (source: Drug Bank)
DRD1 (source: Drug Bank)
DRD2 (source: Drug Bank)
DRD3 (source: Drug Bank)
DRD4 (source: Drug Bank)
DRD5 (source: Drug Bank)
HRH1 (source: Drug Bank)
HTR1A (source: Drug Bank)
HTR1B (source: Drug Bank)
HTR1D (source: Drug Bank)
HTR1E (source: Drug Bank)
HTR2A (source: Drug Bank)
HTR2B (source: Drug Bank)
HTR2C (source: Drug Bank)
HTR3A (source: Drug Bank)
HTR6 (source: Drug Bank)
HTR7 (source: Drug Bank)

Drug Interactions

Interaction Description
clarithromycin - quetiapine This macrolide increases the effect/toxicity of quetiapine (source: Drug Bank)
clarithromycin - quetiapine The macrolide, clarithromycin, may increase the effect and toxicity of quetiapine. (source: Drug Bank)
donepezil - quetiapine Possible antagonism of action (source: Drug Bank)
donepezil - quetiapine Possible antagonism of action (source: Drug Bank)
erythromycin - quetiapine This macrolide increases the effect/toxicity of quetiapine (source: Drug Bank)
erythromycin - quetiapine The macrolide, erythromycin, may increase the effect and toxicity of quetiapine. (source: Drug Bank)
fosphenytoin - quetiapine Phenytoin decreases the effect of quetiapine (source: Drug Bank)
galantamine - quetiapine Possible antagonism of action (source: Drug Bank)
galantamine - quetiapine Possible antagonism of action (source: Drug Bank)
ketoconazole - quetiapine Ketoconazole increases the effect/toxicity of quetiapine (source: Drug Bank)
ketoconazole - quetiapine Ketoconazole increases the effect/toxicity of quetiapine (source: Drug Bank)
phenytoin - quetiapine Phenytoin decreases the effect of quetiapine (source: Drug Bank)
phenytoin - quetiapine Phenytoin decreases the effect of quetiapine (source: Drug Bank)
quetiapine - clarithromycin This macrolide increases the effect/toxicity of quetiapine (source: Drug Bank)
quetiapine - clarithromycin The macrolide, clarithromycin, may increase the effect and toxicity of quetiapine. (source: Drug Bank)
quetiapine - donepezil Possible antagonism of action (source: Drug Bank)
quetiapine - donepezil Possible antagonism of action (source: Drug Bank)
quetiapine - erythromycin This macrolide increases the effect/toxicity of quetiapine (source: Drug Bank)
quetiapine - erythromycin The macrolide, erythromycin, may increase the effect and toxicity of quetiapine. (source: Drug Bank)
quetiapine - ethotoin Phenytoin decreases the effect of quetiapine (source: Drug Bank)
quetiapine - ethotoin Phenytoin decreases the effect of quetiapine (source: Drug Bank)
quetiapine - fosphenytoin Phenytoin decreases the effect of quetiapine (source: Drug Bank)
quetiapine - fosphenytoin Phenytoin decreases the effect of quetiapine (source: Drug Bank)
quetiapine - galantamine Possible antagonism of action (source: Drug Bank)
quetiapine - galantamine Possible antagonism of action (source: Drug Bank)
quetiapine - ketoconazole Ketoconazole increases effect/toxicity of quetiapine (source: Drug Bank)
quetiapine - ketoconazole Ketoconazole increases effect/toxicity of quetiapine (source: Drug Bank)
quetiapine - mephenytoin Phenytoin decreases the effect of quetiapine (source: Drug Bank)
quetiapine - mephenytoin Phenytoin decreases the effect of quetiapine (source: Drug Bank)
quetiapine - phenytoin Phenytoin decreases the effect of quetiapine (source: Drug Bank)
quetiapine - phenytoin Phenytoin decreases the effect of quetiapine (source: Drug Bank)
quetiapine - quinupristin This combination presents an increased risk of toxicity (source: Drug Bank)
quetiapine - quinupristin This combination presents an increased risk of toxicity (source: Drug Bank)
quetiapine - rivastigmine Possible antagonism of action (source: Drug Bank)
quetiapine - rivastigmine Possible antagonism of action (source: Drug Bank)
quinupristin - quetiapine This combination presents an increased risk of toxicity (source: Drug Bank)
tacrine - quetiapine The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Quetiapine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents. (source: Drug Bank)
tacrine - quetiapine The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Quetiapine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents. (source: Drug Bank)
telithromycin - quetiapine Telithromycin may reduce clearance of Quetiapine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Quetiapine if Telithromycin is initiated, discontinued or dose changed. (source: Drug Bank)
tetrabenazine - quetiapine May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects. (source: Drug Bank)
thiothixene - quetiapine May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. (source: Drug Bank)
thiothixene - quetiapine May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. (source: Drug Bank)
toremifene - quetiapine Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration. (source: Drug Bank)
trimethobenzamide - quetiapine Trimethobenzamide and Quetiapine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects. (source: Drug Bank)
trimipramine - quetiapine Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. (source: Drug Bank)
triprolidine - quetiapine Triprolidine and Quetiapine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects. (source: Drug Bank)
triprolidine - quetiapine Triprolidine and Quetiapine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects. (source: Drug Bank)
trospium - quetiapine Trospium and Quetiapine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects. (source: Drug Bank)
voriconazole - quetiapine Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of quetiapine by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of quetiapine if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank)
vorinostat - quetiapine Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). (source: Drug Bank)
ziprasidone - quetiapine Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated. (source: Drug Bank)
zuclopenthixol - quetiapine Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). (source: Drug Bank)

Curated Information ?

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
Contraindicated With

Publications related to quetiapine: 35

No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
PDE7B, NMBR and EPM2A Variants and Schizophrenia: A Case-Control and Pharmacogenetics Study. Neuropsychobiology. 2016. Porcelli Stefano, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association between the HTR2C rs1414334 C/G gene polymorphism and the development of the metabolic syndrome in patients treated with atypical antipsychotics. PeerJ. 2016. Rico-Gomis José María, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Epigenomic mapping and effect sizes of noncoding variants associated with psychotropic drug response. Pharmacogenomics. 2015. Higgins Gerald A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CACNA1C gene and schizophrenia: a case-control and pharmacogenetic study. Psychiatric genetics. 2015. Porcelli Stefano, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetics of quetiapine in healthy volunteers: association with pharmacokinetics, pharmacodynamics, and adverse effects. International clinical psychopharmacology. 2015. Cabaleiro Teresa, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Metabolic side effects and pharmacogenetics of second-generation antipsychotics in children. Pharmacogenomics. 2015. Devlin Angela M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genome-wide association study supports the role of the immunological system and of the neurodevelopmental processes in response to haloperidol treatment. Pharmacogenetics and genomics. 2014. Drago Antonio, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of ABCB1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of quetiapine in healthy volunteers. Pharmacogenetics and genomics. 2013. Kim Kyoung-Ah, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
MC4R rs489693: a clinical risk factor for second generation antipsychotic-related weight gain?. The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP). 2013. Czerwensky Fabian, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacodynamic genetic variants related to antipsychotic adverse reactions in healthy volunteers. Pharmacogenomics. 2013. López-Rodríguez Rosario, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genotypic variation in the SV2C gene impacts response to atypical antipsychotics the CATIE Study. Schizophrenia research. 2013. Ramsey Timothy L, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies. Translational psychiatry. 2013. Nurmi E L, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. Archives of general psychiatry. 2012. Malhotra Anil K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The AmpliChip® CYP450 test and response to treatment in schizophrenia and obsessive compulsive disorder: a pilot study and focus on cases with abnormal CYP2D6 drug metabolism. Genetic testing and molecular biomarkers. 2012. Müller Daniel J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Targeted pharmacogenetic analysis of antipsychotic response in the CATIE study. Pharmacogenomics. 2012. Liu Qian, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Case-control association study for 10 genes in patients with schizophrenia: influence of 5HTR1A variation rs10042486 on schizophrenia and response to antipsychotics. European archives of psychiatry and clinical neuroscience. 2012. Crisafulli Concetta, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Association of common genetic variants with risperidone adverse events in a Spanish schizophrenic population. The pharmacogenomics journal. 2012. Almoguera B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Polymorphisms of the LEP, LEPR and HTR2C gene: obesity and BMI change in patients using antipsychotic medication in a naturalistic setting. Pharmacogenomics. 2011. Gregoor Jochem G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Receptor targets for antidepressant therapy in bipolar disorder: An overview. Journal of affective disorders. 2011. Fountoulakis Konstantinos N, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
KCNH2 pharmacogenomics summary. Pharmacogenetics and genomics. 2010. Oshiro Connie, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis. Pharmacogenomics. 2010. Sicard Michelle N, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genome-wide association study of antipsychotic-induced QTc interval prolongation. The pharmacogenomics journal. 2010. Aberg K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Weight gain related to treatment with atypical antipsychotics is due to activation of PKC-beta. The pharmacogenomics journal. 2010. Pavan C, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Endocannabinoid Pro129Thr FAAH functional polymorphism but not 1359G/A CNR1 polymorphism is associated with antipsychotic-induced weight gain. Journal of clinical psychopharmacology. 2010. Monteleone Palmiero, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Coprescription of tamoxifen and medications that inhibit CYP2D6. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010. Sideras Kostandinos, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in Schizophrenia. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2010. Tiwari Arun K, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Serotonin transporter polymorphisms and early response to antipsychotic treatment in first episode of psychosis. Psychiatry research. 2010. Vázquez-Bourgon Javier, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
DRD4 48 bp VNTR but not 5-HT 2C Cys23Ser receptor polymorphism is related to antipsychotic-induced weight gain. The pharmacogenomics journal. 2009. Popp J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Analytical and bioanalytical chemistry. 2008. Zanger Ulrich M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Ethnic stratification of the association of RGS4 variants with antipsychotic treatment response in schizophrenia. Biological psychiatry. 2008. Campbell Daniel B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Exploring genetic variations that may be associated with the direct effects of some antipsychotics on lipid levels. Schizophrenia research. 2008. de Leon Jose, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A clinical study of the association of antipsychotics with hyperlipidemia. Schizophrenia research. 2007. de Leon Jose, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Risk of extrapyramidal syndrome in schizophrenic patients treated with antipsychotics: a population-based study. Clinical pharmacology and therapeutics. 2007. Yang S-Y, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Adverse drug reactions following nonresponse in a depressed patient with CYP2D6 deficiency and low CYP 3A4/5 activity. Pharmacopsychiatry. 2006. Stephan P L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs. European journal of pharmacology. 2002. Kongsamut Sathapana, et al. PubMed

LinkOuts

Web Resource:
Wikipedia
National Drug Code Directory:
0310-0275-10
DrugBank:
DB01224
ChEBI:
8707
KEGG Compound:
C07397
PubChem Compound:
5002
PubChem Substance:
46504800
9601
IUPHAR Ligand:
50
Drugs Product Database (DPD):
2240862
ChemSpider:
4827
Therapeutic Targets Database:
DAP000001
FDA Drug Label at DailyMed:
0584dda8-bc3c-48fe-1a90-79608f78e8a0

Clinical Trials

These are trials that mention quetiapine and are related to either pharmacogenetics or pharmacogenomics.

No trials loaded.

NURSA Datasets

provided by nursa.org

No NURSA datasets available.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, PubChem.